156 related articles for article (PubMed ID: 2173410)
1. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
Domagala W; Woźniak L; Lasota J; Weber K; Osborn M
Am J Pathol; 1990 Nov; 137(5):1059-64. PubMed ID: 2173410
[TBL] [Abstract][Full Text] [Related]
2. Vimentin expression in different types of breast carcinoma immunohistochemical study.
Essa TM; el Tatawi FA; Hamdi KN; Arafa WA
J Egypt Soc Parasitol; 1996 Aug; 26(2):433-42. PubMed ID: 8754651
[TBL] [Abstract][Full Text] [Related]
3. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.
Domagala W; Harezga B; Szadowska A; Markiewski M; Weber K; Osborn M
Am J Pathol; 1993 Mar; 142(3):669-74. PubMed ID: 8384406
[TBL] [Abstract][Full Text] [Related]
4. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
Domagala W; Lasota J; Bartkowiak J; Weber K; Osborn M
Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
[TBL] [Abstract][Full Text] [Related]
5. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.
Domagala W; Lasota J; Dukowicz A; Markiewski M; Striker G; Weber K; Osborn M
Am J Pathol; 1990 Dec; 137(6):1299-304. PubMed ID: 1701960
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
Domagala W; Striker G; Szadowska A; Dukowicz A; Weber K; Osborn M
Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
[TBL] [Abstract][Full Text] [Related]
7. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
8. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
Gamallo C; Palacios J; Suarez A; Pizarro A; Navarro P; Quintanilla M; Cano A
Am J Pathol; 1993 Apr; 142(4):987-93. PubMed ID: 7682767
[TBL] [Abstract][Full Text] [Related]
9. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma].
Alexiev B; Valkov I; Popov A
Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942
[TBL] [Abstract][Full Text] [Related]
11. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
12. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
15. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
16. Paucity of fibronectin in invasive lobular carcinoma of breast.
D'Ardenne AJ; Barnard NJ
J Pathol; 1989 Mar; 157(3):219-24. PubMed ID: 2538611
[TBL] [Abstract][Full Text] [Related]
17. Low, intermediate and high grade breast carcinomas as determined by histotyping, immunohistochemical prognosticators and histological grading.
Martinazzi M; Crivelli F; Zampatti C; Pisani P
Pathologica; 1992; 84(1089):33-47. PubMed ID: 1323096
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
20. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
